<DOC>
	<DOCNO>NCT01689870</DOCNO>
	<brief_summary>This open label , two-phase study combine dose escalation Phase 1 proof-of-concept Phase 2 patient unresectable metastatic melanoma , treatment ipilimumab indicate . The purpose Phase 1 determine Anti-OX40 Maximum Tolerated Dose ( MTD ) secondary objective anti-OX40 pharmacokinetics , biological activity tumor response assess Immune-related Response Criteria . The purpose Phase 2 determine tumor response ( irRC ) secondary objective anti-OX40 pharmacokinetics , biological activity Safety/Tolerability .</brief_summary>
	<brief_title>Study Combination Anti-OX40 Ipilimumab Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients unresectable metastatic melanoma , treatment Ipilimumab indicate Radiologically measurable disease immunerelated Response Criteria ECOG performance status 01 . Anticipated lifespan great 12 week . At time day 1 study , patient must least 3 week since surgery At time day 1 study , patient brain metastasis must asymptomatic , least 8 week without tumor progression whole brain radiotherapy , least 4 week since craniotomy resection stereotactic radiosurgery , least 3 week without new brain metastasis evidence MRI/CT The following laboratory parameter must within range specify : Hemoglobin≥ 9 g/dL , WBC≥ 3.0 x 109/L , INR≤ 1.5 , Total Bilirubin≤ 1.9 g/dL &amp; AST/ALT≤ 3 x ULN Have inform treatment option . At least 18 year . Able willing give valid write informed consent . Any contraindication ipilimumab/Yervoy® . Prior exposure ipilimumab/Yervoy® Prior exposure AntiOX40 mouse monoclonal antibody . History severe allergic reaction unknown allergen antiOX40 Autoimmune disease except autoimmune thyroiditis vitiligo . Unresolved immune related adverse event follow prior biological therapy . Metastatic disease central nervous system therapeutic option , include radiotherapy , may available . Known immunodeficiency HIV , Hepatitis B Hepatitis C positivity . Other serious illness ( e.g. , serious infection require antibiotic ) . Participation clinical trial involve another investigational agent within 4 week prior day 1 study . Mental impairment may compromise ability give informed consent comply requirement study . Lack availability immunological clinical followup assessment . Women breast feed pregnant evidence positive serum pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) do within 72 hour first dose . Women childbearing potential use medically acceptable mean contraception duration study . Any condition , clinical judgment treat physician , likely prevent patient comply aspect protocol may put patient unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>OX40</keyword>
	<keyword>Anti-OX40</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Melanoma</keyword>
</DOC>